

What is claimed:

- 1) Use of a BCMAxCD3 bispecific antibody for the manufacture of a medicament for the treatment of a cancer in a subject, wherein the medicament is to be administered in combination with an anti-CD38 antibody, wherein the cancer is a multiple myeloma, and wherein:
 - a) the BCMAxCD3 bispecific antibody comprises a BCMA binding domain and a CD3 binding domain, wherein the BCMA binding domain comprises the VH of SEQ ID NO: 29 and the VL of SEQ ID NO: 30, and wherein the CD3 binding domain comprises the VH of SEQ ID NO: 39 and the VL of SEQ ID NO: 40; and
 - b) the anti-CD38 antibody comprises the VH of SEQ ID NO: 4 and the VL of SEQ ID NO: 5.
- 2) Use of an anti-CD38 antibody for the manufacture of a medicament for the treatment of a cancer in a subject, wherein the medicament is to be administered in combination with a BCMAxCD3 bispecific antibody, wherein the cancer is a multiple myeloma, and wherein:
 - a) the anti-CD38 antibody comprises the VH of SEQ ID NO: 4 and the VL of SEQ ID NO: 5; and
 - b) the BCMAxCD3 bispecific antibody comprises a BCMA binding domain and a CD3 binding domain, wherein the BCMA binding domain comprises the VH of SEQ ID NO: 29 and the VL of SEQ ID NO: 30, and the CD3 binding domain comprises the VH of SEQ ID NO: 39 and the VL of SEQ ID NO: 40.
- 3) Use of a BCMAxCD3 bispecific antibody and an anti-CD38 antibody for the manufacture of a medicament for the treatment of a cancer in a subject, wherein the cancer is a multiple myeloma, and wherein:
 - a) the BCMAxCD3 bispecific antibody comprises a BCMA binding domain and a CD3 binding domain, wherein the BCMA binding domain comprises the VH of SEQ ID NO: 29 and the VL of SEQ ID NO: 30, and the CD3 binding domain comprises the VH of SEQ ID NO: 39 and the VL of SEQ ID NO: 40; and
 - b) the anti-CD38 antibody comprises the VH of SEQ ID NO: 4 and the VL of SEQ ID NO: 5.
- 4) The use of any one of claims 1-3, wherein
 - a) the anti-CD38 antibody is to be administered to the subject prior to the BCMAxCD3 bispecific antibody being administered; and/or
 - b) the BCMAxCD3 bispecific antibody is an IgG4 isotype and comprises phenylalanine at position 405 and arginine at position 409 in the HC1 and leucine at position 405 and lysine at position 409 in the HC2, wherein residue numbering is according to the EU Index.
- 5) The use of claim 4b), wherein the BCMAxCD3 bispecific antibody further comprises proline at position 228, alanine at position 234 and alanine at position 235 in both the HC1 and the HC2.
- 6) The use of claim 5, wherein the BCMAxCD3 bispecific antibody comprises the HC1 of SEQ ID NO: 31, the LC1 of SEQ ID NO: 32, the HC2 of SEQ ID NO: 41 and the LC2 of SEQ ID NO: 42.

- 7) The use of any one of claims 1-6, wherein the subject is relapsed or refractory to treatment with the anti-CD38 antibody, lenalidomide, bortezomib, pomalidomide, carfilzomib, elotuzumab, ixazomib, melphalan or thalidomide, or any combination thereof.
- 8) The use of claim 7, wherein the subject is relapsed or refractory to treatment with the anti-CD38 antibody.
- 9) The use of any one of claims 1-8, wherein:
 - a) the multiple myeloma:
 - I. is a newly diagnosed multiple myeloma; or
 - II. is a relapsed or a refractory multiple myeloma; and/or
 - b) the multiple myeloma is a high-risk multiple myeloma.
- 10) The use of claim 9b), wherein the subject having the high-risk multiple myeloma has one or more chromosomal abnormalities comprising:
 - I. t(4;14)(p16;q32);
 - II. t(14;16)(q32;q23);
 - III. del17p;
 - IV. 1qAmp;
 - V. t(4;14)(p16;q32) and t(14;16)(q32;q23);
 - VI. t(4;14)(p16;q32) and del17p;
 - VII. t(14;16)(q32;q23) and del17p; or
 - VIII. t(4;14)(p16;q32), t(14;16)(q32;q23) and del17p, or any combination thereof.
- 11) The use of any one of claims 1-10, wherein:
 - a) the anti-CD38 antibody is an IgG1 isotype; and/or
 - b) the anti-CD38 antibody comprises the HC of SEQ ID NO: 12 and the LC of SEQ ID NO: 13;
- 12) The use of any one of claims 1-11, wherein:
 - a) the anti-CD38 antibody is to be administered at a dose of between about 8 mg/kg and about 16 mg/kg; and/or
 - b) wherein the BCMAxCD3 bispecific antibody and the anti-CD38 antibody are to be administered by an intravenous injection or wherein the BCMAxCD3 bispecific antibody is to be administered by an intravenous injection and the anti-CD38 antibody is to be administered by a subcutaneous injection.
- 13) The use of any one of claims 1-12, wherein the subject is a human.
- 14) The use of any one of claims 1-13, wherein the use further comprises one or more anti-cancer therapies to be administered to the subject.
- 15) The use of claim 14, wherein the one or more anti-cancer therapies is selected from the group consisting of:

- i) an autologous stem cell transplant (ASCT), radiation, surgery, a chemotherapeutic agent, an immunomodulatory agent and a targeted cancer therapy; or
 - ii) lenalidomide, thalidomide, pomalidomide, bortezomib, carfilzomib, elotuzumab, ixazomib, melphalan, prednisone or dexamethasone, or any combination thereof.
- 16) The use of any one of claims 1-15, wherein:
- a) the anti-CD38 antibody is to be administered or provided for administration in a pharmaceutical composition comprising between about 20 mg/mL to about 120 mg/mL of the anti-CD38 antibody in about 25 mM acetic acid, about 60 mM sodium chloride, about 140 mannitol and about 0.04% w/v polysorbate-20 (PS-20); at pH about 5.5; and/or
 - b) the anti-CD38 antibody is to be administered or provided for administration in a pharmaceutical composition comprising about 1,800 mg of the anti-CD38 antibody and about 30,000 U of rHuPH20.
- 17) The use of claim 16b), wherein the anti-CD38 antibody is to be administered or provided for administration in a pharmaceutical composition comprising about 120 mg/mL of the anti-CD38 antibody and about 2,000 U/mL of rHuPH20.
- 18) The use of claim 17, wherein the anti-CD38 antibody is to be administered or provided for administration in a pharmaceutical composition comprising
- i) between about 5 mM and about 15 mM histidine;
 - ii) between about 100 mM and about 300 mM sorbitol;
 - iii) between about 0.01% w/v and about 0.04 % w/v PS-20; and
 - iv) between about 1 mg/mL and about 2 mg/mL methionine, at a pH of about 5.5-5.6,
- 19) The use of claim 18, wherein the anti-CD38 antibody is to be administered or provided for administration in a pharmaceutical composition comprising
- I. about 1,800 mg of the anti-CD38 antibody;
 - II. about 30,000 U of rHuPH20;
 - III. about 10 mM histidine;
 - IV. about 300 mM sorbitol;
 - V. about 0.04 % (w/v) PS-20; and
 - VI. about 1 mg/mL methionine, at a pH of about 5.6.
- 20) The use of claim 19, wherein the anti-CD38 antibody is to be administered or provided for administration in a pharmaceutical composition comprising
- A. about 120 mg/mL of the anti-CD38 antibody;
 - B. about 2,000 U/mL of rHuPH20;
 - C. about 10 mM histidine;
 - D. about 300 mM sorbitol;
 - E. about 0.04 % (w/v) PS-20; and

F. about 1 mg/mL methionine, at a pH of about 5.6.

- 21) A pharmaceutical composition comprising a BCMAxCD3 bispecific antibody comprising a BCMA binding domain comprising the VH of SEQ ID NO: 29 and the VL of SEQ ID NO: 30 and a CD3 binding domain comprising the VH of SEQ ID NO: 39 and the VL of SEQ ID NO: 40, and an anti-CD38 antibody comprising the VH of SEQ ID NO: 4 and the VL of SEQ ID NO: 5.
- 22) The pharmaceutical composition of claim 21, wherein:
- a) the BCMAxCD3 bispecific antibody comprises the HC1 of SEQ ID NO: 31, the LC1 of SEQ ID NO: 32, the HC2 of SEQ ID NO: 41 and the LC2 of SEQ ID NO: 42 and the anti-CD38 antibody comprises the HC of SEQ ID NO: 12 and the LC of SEQ ID NO: 13; and/or
 - b) the pharmaceutical composition is a non-fixed combination.
- 23) The pharmaceutical composition of claim 22b), comprising:
- a) from about 20 mg/mL to about 120 mg/mL of the anti-CD38 antibody in about 25 mM acetic acid, about 60 mM sodium chloride, about 140 mannitol and about 0.04% w/v polysorbate-20 (PS-20); at pH about 5.5; or
 - b) about 1,800 mg of the anti-CD38 antibody and about 30,000 U of rHuPH20.
- 24) The pharmaceutical composition of claim 23b) comprising about 120 mg/mL of the anti-CD38 antibody and about 2,000 U/mL of rHuPH20.
- 25) The pharmaceutical composition of claim 24, wherein the pharmaceutical composition further comprises one or more excipients.
- 26) The pharmaceutical composition of claim 25, wherein the one or more excipients is histidine, methionine, sorbitol or polysorbate-20 (PS-20), or any combination thereof.
- 27) The pharmaceutical composition of claim 26, wherein the pharmaceutical composition comprises
- I. between about 100 mg/mL and about 120 mg/mL of the anti-CD38 antibody;
 - II. between about 5 mM and about 15 mM histidine;
 - III. between about 100 mM and about 300 mM sorbitol;
 - IV. between about 0.01% w/v and about 0.04 % w/v PS-20; and
 - V. between about 1 mg/mL and about 2 mg/mL methionine, at a pH of about 5.5-5.6,
- 28) The pharmaceutical composition of claim 27, wherein the pharmaceutical composition:
- A. comprises about 10 mM histidine;
 - B. comprises about 300 mM sorbitol;
 - C. comprises about 0.04% (w/v) PS-20;
 - D. comprises about 1 mg/mL methionine;
 - E. comprises
 - a. about 1,800 mg of the anti-CD38 antibody;
 - b. about 30,000 U of rHuPH20;

- c. about 10 mM histidine;
- d. about 300 mM sorbitol;
- e. about 0.04 % (w/v) PS-20; and
- f. about 1 mg/mL methionine, at a pH of about 5.6; and/or

F. comprises

- a. about 120 mg/mL of the anti-CD38 antibody;
- b. about 2,000 U/mL of rHuPH20;
- c. about 10 mM histidine;
- d. about 300 mM sorbitol;
- e. about 0.04 % (w/v) PS-20; and
- f. about 1 mg/mL methionine, at a pH of about 5.6.

29) A kit comprising the pharmaceutical composition of any one of claims 21-28.